By checking the pulse of your organization, you can identify gaps and develop a plan for how to address them, so you can make the right decisions at the right time.
Sterile suspensions are particularly difficult to manufacture. This technical article covers factors for success, including particle size, vehicle formulation, and considerations for high-shear mixing.
To address the ongoing public health crisis related to opioid abuse, Xtampza ER, an oral ER abuse-deterrent formulation of oxycodone, has been developed to resist the ability of abusers to tamper with the product and alter the route of administration.
Using a case study, the author demonstrates how comparative statistical analysis enabled his team to improve the yield of a component used in API synthesis by more than 2.5 x 108 U/batch, with the added benefit of improved process predictability.
Understand the strategies which can be employed at the different stages of development when choosing parenteral dosage forms.
To take advantage of the growing HPAPI market, a company must have the proper controls in place to safely handle these potent compounds and successfully bring its drug to market.
Joe Principe, Vice President of Strategic Partnerships, Patheon, discusses the new set of “must-haves” that are emerging from the increased need for flexibility in outsourced manufacturing partnerships.
Single-use technologies are being seen as the solution to flexibly and cost-effectively address many of the challenges around creating biologics manufacturing capacity.
Pharmaceutical manufacturer and developer, Penn Pharma, has confirmed that its new contained manufacturing facility for producing highly potent products is on track for opening Q1 2013 at an exclusive event held at the British Embassy, Madrid during ICSE.
To be successful, new treatments require superior real world outcomes providing market differentiation and delivering the best outcomes to you, your stakeholders, and most importantly the patients who depend on your therapy.
Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Enterprises Ltd. with a vast network of development and manufacturing facilities in North America,Europe and Asia. We offer a vast array of services, which include Drug Discovery & Development, Clinical Supply of API & Dosage Forms, Commercial Manufacturing & Supply of API, KSMs, RSMs, Intermediates and Finished Dosage Forms. At Piramal, we are committed to fulfil our clients’ API development & manufacturing requirements, across all phases of the drug life cycle.
Patheon is transforming the way pharmaceuticals are made with a simplified, end-to-end supply chain for pharmaceutical and biopharmaceutical companies of all sizes. Drug substances and drug products.